Figure 4 | Scientific Reports

Figure 4

From: A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge

Figure 4

Neutralisation titres of serum antibodies against distinct EV71 strains. (a) TW2272/98 (C2 genogroup), (b) 200307025 (B4 genogroup), and (c) 20080738 (B5 genogroup). Sera were collected from mice at 2 weeks after the third immunisation with PBS or formalin-inactivated EV71 alone or with CpG and were serially diluted (23–212), mixed with the EV71 virus (strain TW2272/98, 200307025, or 20080738), and used to infect RD cells. After 4 days, the neutralisation titre was read as the highest dilution that resulted in the virus producing no cytopathic effect. Values shown are means ± SEMs of six mice in each experimental group; *p < 0.05. One representative study of three with similar results is shown. RD cells: rhabdomyosarcoma cells.

Back to article page